Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

Class III Obesity Is Associated with Worse Overall Survival in Previously Untreated Younger Patients with Acute Myeloid Leukemia Enrolled on SWOG 1203

Michelle Y. Zhang, Megan Othus, Kerry K McMillen, Harry P. Erba, Guillermo Garcia-Manero, John Pagel, Mohamed Sorror, Mary-Elizabeth M. Percival

Blood (2023) 142 (Supplement 1): 2863.

https://doi.org/10.1182/blood-2023-189455

Published: 2023

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)

Kami J. Maddocks, MD, John Pagel, MD PhD, John C. Byrd, MD, Scott Stromatt, Farrukh Awan, MD MS

Blood (2014) 124 (21): 4671.

https://doi.org/10.1182/blood.V124.21.4671.4671

Published: 2014

Journal Articles

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2014) 124 (21): 3331.

https://doi.org/10.1182/blood.V124.21.3331.3331

Published: 2014

Journal Articles

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Theodore A. Gooley, PhD, Thomas Chauncey, MD PhD, John Pagel, MD PhD, Brian G. Till, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, William I. Bensinger, MD, Leona Holmberg, MD PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Stephen D. Smith, MD, Edward N. Libby, MD, David G Maloney, MDPhD, Lorinda A. Soma, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2014) 124 (21): 3967.

https://doi.org/10.1182/blood.V124.21.3967.3967

Published: 2014

Journal Articles

Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Mazyar Shadman, MD MPH, Raya Mawad, MD, Carol Dean, MPH, BSN, Kathleen Shannon-Dorcy, RN,PhD, Vicky Sandhu, MD MPH, Paul C. Hendrie, MD PhD, Bart L. Scott, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, John Pagel, MD PhD, Elihu H. Estey, MD

Blood (2014) 124 (21): 3732.

https://doi.org/10.1182/blood.V124.21.3732.3732

Published: 2014

Journal Articles

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Raya Mawad, MD, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Bart L Scott, MD, Brent L. Wood, MD PhD, Carol Dean, MPH, BSN, Vicky Sandhu, MD MPH, H. Joachim Deeg, MD, Roland B. Walter, MD PhD MS, Lixia Wang, PhD, Jack Singer, MD, Elihu H. Estey, MD, John Pagel, MD PhD

Blood (2014) 124 (21): 3690.

https://doi.org/10.1182/blood.V124.21.3690.3690

Published: 2014

Journal Articles

Pre-Targeted Radioimmunotherapy Employing a Recombinant Bispecific Antibody Using a Murine Xenograft Model of Human Leukemia

Aimee L. Kenoyer, BS, Yukang Lin, PhD, Johnnie J. Orozco, MD PhD, Ethan Balkin, Don Hamlin, BS, Alexandra H. Hernandez, BS, Chen Fang, PhD, Kelly Laird, Sofia H.L. Frost, PhD, Mark Hylarides, PhD, Kelly D. Orcutt, PhD, D Scott Wilbur, PhD, K. Dane Wittrup, PhD, Oliver W. Press, MD PhD, John Pagel, MD PhD

Blood (2014) 124 (21): 3749.

https://doi.org/10.1182/blood.V124.21.3749.3749

Published: 2014

NARROW

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Class III Obesity Is Associated with Worse Overall Survival in Previously Untreated Younger Patients with Acute Myeloid Leukemia Enrolled on SWOG 1203

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Pre-Targeted Radioimmunotherapy Employing a Recombinant Bispecific Antibody Using a Murine Xenograft Model of Human Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only